Amoy Diagnostics Co., Ltd (AmoyDx), a China-based innovative molecular diagnostics company (SZSE: 300685), announced that it has entered into a Companion Diagnostic Collaboration Agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical company. According to the Agreement, AmoyDx's self-developed product AmoyDx® HRD Complete Panel, once approved, would serve as the companion diagnostic for the PARP inhibitor Lynparza® (olaparib), that is jointly developed and commercialized by AstraZeneca and Merck, known as MSD outside the United States and Canada. Olaparib is approved in China for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to 1st-line platinum-based chemotherapy in combination with bevacizumab, and whose cancer is associated with homologous recombination deficiency (HRD)-positive status.
At the end of 2021, AmoyDx signed a global strategic Master Collaboration Agreement with AstraZeneca for oncology companion diagnostics. This early implementation in the field of ovarian cancer companion diagnostics will expand the identification of patients who could benefit from olaparib treatment for ovarian cancer through HRD detection. Several China and international guidelines and expert consensuses have recognized HRD as a predictive biomarker for ovarian cancer patients receiving PARP inhibitor treatment. AmoyDx's proprietary algorithm, user-friendly and fast operation experience, have established its internationally leading position in the HRD detection field. The collaboration between AmoyDx and AstraZeneca on HRD companion diagnostics will enable more Chinese patients to access olaparib as soon as possible.
Regarding this collaboration, Dr Zheng Limou, the founder and chairman of AmoyDx, stated: "We are delighted to expand our companion diagnostic collaboration with AstraZeneca. We hope that AmoyDx's products can help physicians to identify ovarian cancer patients who could be eligible for treatment with olaparib and improve outcomes for ovarian cancer patients in China." As a leading precision oncology diagnostic company, AmoyDx adheres to the principles of clinical and patient needs, continuously develops decentralized compliant companion diagnostic products, and contributes to the standardization and rapid development of the PARP inhibitor biomarker testing ecosystem. From obtaining NMPA-registered BRCA testing products exclusively in China to independently innovating HRD testing and scoring algorithms, AmoyDx looks forward to working with AstraZeneca and MSD to jointly advance the clinical application of precision oncology diagnosis and treatment.